Case Study 

RedKnight is delighted to announce a proposal it provided bid-writing support for, which was submitted to Innovate UK’s Investor Accelerator Pilot in July 2017 has recently been awarded, securing TeloNostiX Ltd, a Cardiff based small to medium-sized enterprise (SME), £130,636. The funding, jointly provided by Innovate UK and private investment partner, Syncona Ltd, will allow for further development work to be carried out on TeloNostix’s powerful cancer prognosis test using Single Telomere Length Analysis (STELA). STELA provides accurate prognostic information for individual cancer patients, which helps address two significant global healthcare challenges i.e. patient stratification and precision medicine.

The funding  will help TeloNostiX achieve two specific objectives critical to the development of their technology. Firstly, they will demonstrate the technical feasibility of telomere testing in the routine clinical management of patients suffering from Chronic Lymphocytic Leukemia (CLL) by performing a logistical evaluation within an operational environment. Secondly, they will create a financial justification for NHS adoption of STELA by undertaking health economics modelling. The key focus will be to evaluate the potential for using STELA to stratify CLL patients into risk groups based on whether they will undergo clinical progression and require treatment. Also, the funding will afford TeloNostiX to engage with a global distributor of telomere tests and analyse the cancer prognostics market using current market reports to further quantify the business opportunity.

Want to find out more? Get in touch today.